Table 1.
Comparison of baseline characteristics of patients infected with S. epidermidis isolates according to their teicoplanin-susceptibility.
| Characteristic, N (%) | Teico-S groupa (n = 311) | Teico-NS groupb (n = 17) | P value |
|---|---|---|---|
| Demographics | |||
| Age, median (IQR), years | 68.0 (57.0–79.0) | 77.0 (70.5–83.0) | 0.01 |
| Male | 187 (60.1) | 9 (52.9) | 0.62 |
| Underlying disease | |||
| Hypertension | 165 (53.1) | 8 (47.1) | 0.63 |
| Diabetes mellitus | 117 (37.6) | 9 (52.9) | 0.21 |
| Congestive heart disease | 16 (5.1) | 0 | 1.00 |
| Cerebrovascular accident | 85 (27.3) | 2 (11.8) | 0.26 |
| Chronic liver disease | 21 (6.8) | 1 (5.9) | 1.00 |
| Chronic kidney disease | 29 (9.3) | 1 (5.9) | 1.00 |
| Solid cancer | 55 (17.7) | 1 (5.9) | 0.32 |
| Hematological malignancy | 4 (1.3) | 1 (5.9) | 0.24 |
| COVID-19 infectionc | 9 (2.9) | 5 (29.4) | 0.04 |
| Previous antibiotic use | 273 (87.8) | 15 (88.2) | 1.00 |
| Glycopeptide antibiotics | 122 (39.2) | 4 (23.5) | 0.31 |
| Vancomycin | 40 (12.9) | 0 (0.0) | 0.24 |
| Teicoplanin | 101 (32.5) | 4 (23.5) | 0.60 |
| Source of isolates | |||
| Blood | 236 (81.1) | 15 (88.2) | 0.36 |
| Oxacillin-resistance | 275 (88.4) | 17 (100.0) | 0.23 |
Data are presented as the number of patients (with the corresponding percentage in parentheses) unless otherwise specified.
Teico-S teicoplanin-susceptible, Teico-NS teicoplanin-non-susceptible, IQR interquartile range, MIC minimal inhibitory concentration.
aTeicoplanin MIC values < 16 mg/L.
bTeicoplanin MIC values ≥ 16 mg/L.
cPatients infected with COVID-19 were only present in 2020 and 2021. (n = 6 and 8, respectively).